AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03694314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: 200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).
Study NCT03694314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mL placebo fruit juice with no effect on the hypothesized outcome.
Study NCT00415584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Study NCT03311230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive social incentive
Description: A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
Study NCT03311230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive social incentive
Description: Participants in this intervention will be competing against each other in the game.
Study NCT03311230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative social incentive
Description: Participants in this intervention will be working with each other in the game.
Study NCT02500914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-002
Description: SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
Study NCT00077311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: 200 mcg sub Q on day 1 of each cycle if HgB \< or = 11 g/dL
Study NCT00077311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg sub Q day 2 of each cycle
Study NCT00077311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/sq m IV over 1 hr Day 1 of each cycle
Study NCT00077311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/sq m IV over 1 hr Day 1 of each cycle
Study NCT00077311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNP7787
Description: 40 g IV over 30 min Day 1 of each cycle
Study NCT04398615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable watch device
Description: Every study participant will be given a wearable watch device at the beginning of the study and will be instructed on how to use the device and to wear it continuously throughout the duration of the study (6 months total follow-up). The device will register biometric data and automatically archived. During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.
Study NCT02961374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO
Study NCT01871493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SQ
Study NCT02961374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT02291484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac CT scan
Description: CT-guided management
Study NCT03716674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metronome
Description: Patients completed 4 walking sessions of at least 10 minutes each. During each session, no auditory rhythm was given, or the rhythm of a Rhythmic Auditory Stimulation (RAS) adapted to the pace of comfort of each patient using a metronome was broadcasted via headphones. In all, 4 conditions were tested: walk with no RAS or an isochronous RAS or a random RAS or a RAS with an autocorrelated metronome rhythm.
Study NCT01068301 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Plerixafor
Description: Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
Study NCT00911313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets (Femara; Novartis Pharma, Switzerland)
Description: 2.5 mg letrozole daily from day 3 of the menses for 5 days
Study NCT00911313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin HCl (Cidophage®; CID,Cairo, Egypt)
Description: metformin HCl 1500 daily for 6-8 weeks
Study NCT00911313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)
Description: 150 mg CC for 5 days starting from day 3 of menstruation
Study NCT02529878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1/Paclitaxel chemotherapy plus Apatinib
Description: S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
Study NCT02687490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 125 mg/m2, D1, D8, D15
Study NCT04275843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Diet
Description: Consuming an traditional whole foods based diet for 4 weeks.
Study NCT04275843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modern Diet
Description: Consuming an processed formulation of the traditional diet for 4 weeks.
Study NCT03975387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX295
Description: ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
Study NCT03277378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lead placement followed by BurstDR stimulation
Description: lead placement followed by BurstDR stimulation
Study NCT02810067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnel + AlloDerm
Description: A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm).
Study NCT02810067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel + Novomatrix
Description: A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
Study NCT03230383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
Study NCT01871493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SQ
Study NCT02957435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplerenone
Description: (Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
Study NCT00474201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: lopinavir 400 mg + ritonavir 100 mg twice daily for 2 weeks
Study NCT00474201 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Gemfibrozil
Description: Control arm (no intervention used in this arm)
Study NCT03207464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]Methylreboxetine
Description: 8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a \[C-11\]MRB PET scan and a MRI scan.
Study NCT02069912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative depression care management
Description: Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
Study NCT03715972 — intervention group
Intervention type: DRUG
Intervention: Hydroxyurea
Description: info included in arm group
Study NCT03715972 — intervention group
Intervention type: DRUG
Intervention: Acetazolamide
Description: Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.
Study NCT02397954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.
Study NCT03928262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.
Study NCT02621489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: 2 mg Once Weekly
Study NCT02621489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin kwickpen
Description: Humulin kwickpen 10U QD at bedtime
Study NCT02621489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin kwickpen
Description: Humulin kwickpen 10U QD at bedtime
Study NCT02621489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1g BID
Study NCT02621489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1g BID
Study NCT03230383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.
Study NCT01007240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyethylenimine (PEI) nanoparticles.
Study NCT01033279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring and adjustment of oral anticoagulation
Description: Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
Study NCT03853642 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
Study NCT04875364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: 2mg of Eszopiclone just before going to sleep.
Study NCT04875364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: Constant oxygen flow at 4 Liters per minutes for the duration of time in bed via nasal cannula.
Study NCT04875364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: A standard CPAP device will be provided using the settings as prescribed by the treating physician.
Study NCT00790114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: Oral, day 1-12
Study NCT00790114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: single dose, twice during treatment
Study NCT00790114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: single dose, twice during treatment
Study NCT01583244 — intervention group
Intervention type: DRUG
Intervention: No Intervention (subjects were previously treated with Orencia®)
Description: No Intervention
Study NCT00234156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oral fructose and high fat diet
Description: High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (\~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (\~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours.
Study NCT01542021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix injection
Description: Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
Study NCT01542021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix injection
Description: Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
Study NCT01542021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Study NCT03776994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinations on Day 0, Day 28, and Day 140
Description: The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)
Study NCT04676490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RECORD-ED Card
Description: Low-cost and low-tech recordable audio card containing language-concordant discharge instructions for families of children under age 10 presenting to the ED for asthma exacerbations with no or public insurance and a preference for English or Spanish. Recordable cards allow for multiple audio reviews of the instructions by multiple caregivers without dependence on access to the internet or smartphone technologies.
Study NCT04676490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RECORD-ED Patient Portal
Description: Audio recorded, language concordant discharge instructions via patient portal
Study NCT01341340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus Eluting BVS
Description: Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
Study NCT04625465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).
Study NCT04625465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.
Study NCT04625465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Text Messaging
Description: Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.
Study NCT03425578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MSG
Description: 150 mg/kg body mass monosodium glutamate (MSG).
Study NCT03425578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MSG
Description: 150 mg/kg body mass monosodium glutamate (MSG).
Study NCT03425578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHO
Description: 75g CHO (i.e. dextrose)
Study NCT03425578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHO
Description: 75g CHO (i.e. dextrose)
Study NCT03425578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo A
Description: A non-caloric placebo composed of table salt (NaCl) and sucralose (Splenda).
Study NCT03425578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo B
Description: A non-caloric placebo composed of flavoured water.
Study NCT04604444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech
Description: Intensive Comprehensive Aphasia (ICAP) and Apraxia of Speech Program
Study NCT03858725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D569 Tab.
Description: D569 Tab. 1T single oral administration under fasting condition
Study NCT03268850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
Study NCT03268850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wage Reimbursement A
Description: Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria.
Study NCT03268850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wage Reimbursement B
Description: Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria.
Study NCT04299971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate Tablets
Description: The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead.
Study NCT04299971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib tablet
Description: The tofacitinib group is prescribed with tofacitinib tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of tofacitinib is maintained for another 24 weeks, otherwise (resistant), patients would be given methotrexate (15.0mg.qw.p.o.) for 24 weeks instead.
Study NCT03742232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG3350
Description: PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
Study NCT03742232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrogol 4000
Description: SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
Study NCT01372202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.